Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
about
Chemotherapy for metastatic and recurrent cervical cancerDo selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trialsEffects of Acanthus ebracteatus Vahl on tumor angiogenesis and on tumor growth in nude mice implanted with cervical cancer.Angiogenesis and antiangiogenic agents in cervical cancer.Chitosan hydrogel for localized gene silencingA novel synthetic small molecule YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study.Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.A new antiproliferative and antioxidant peptide isolated from Arca subcrenata.Early transcriptional pattern of angiogenesis induced by EGCG treatment in cervical tumour cells.Emerging biological treatments for uterine cervical carcinoma.Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.Association between vascular endothelial growth factor expression and lymph node metastasis in cervical cancer: A meta-analysis.Elevated expression of thymosin β4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1α in early-stage cervical cancers.ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis.VEGF +936 C/T Genetic Polymorphism in Patients with Cervical Dysplasia.
P2860
Q24198084-9C039E3A-F228-4264-8D21-60B7BA0AC2DCQ33579159-F0F39EFE-0ECF-4CC4-A03F-9DBE51E34A21Q34414509-CE9D20CA-3066-43D7-9579-CB6B3F31CA72Q34655335-6164A141-32BD-4519-A2B7-F7A8B2E4FE7BQ35001428-191AA51B-54A8-4155-8B0B-FE86EC97D850Q36279494-1B0FDB35-749E-4759-958C-6792630270E5Q36937488-EE98685F-CD28-4288-AABB-11D77CA121E7Q36937771-5EE3BAAF-3BF0-4A3C-9BEE-187657F5D550Q37040029-276799FD-B0C9-4C30-A653-4E395B3B00F3Q37294809-4EEA4A5B-A885-4CE3-BED3-4B962EF8618DQ37540968-EE5CE849-EAE1-4C4E-A477-D40E83E6767DQ39311151-53C51E8B-7764-4835-8E2E-432D64E5806AQ40686865-250435B8-5342-490D-A174-629A3C5F41E7Q44045026-F238BA4F-30D1-420F-AB9B-C30F1B05C129Q46128098-8EA53920-8461-4CF8-BCE2-2F86D2BABB48Q50929913-3CA61BCC-3DBD-4E17-9B64-DEF47DE21258Q55194696-D1BA7B1C-0E9E-4F13-AA8F-F421CAA3792C
P2860
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@en
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@nl
type
label
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@en
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@nl
prefLabel
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@en
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@nl
P2860
P356
P1476
Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
@en
P2093
Bradley J Monk
Lyndsay J Willmott
P2860
P304
P356
10.1586/ERA.09.58
P577
2009-07-01T00:00:00Z